about
Temporary Single-Cell Coating for Bioprocessing with a Cationic Polymer.Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.Condensin II mutation causes T-cell lymphoma through tissue-specific genome instabilityKeratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation.Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factorCyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerPharmacogenetics of genes across the doxorubicin pathway.Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide.Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma.Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?Institutional profile: pharmacogenomics research at Newcastle University.A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphismTwo minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapyPharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracilInhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductaseDetection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic BiomarkersA novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cellsGenetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial
P50
Q33594355-8E77A3FB-975E-4461-85BD-7901E910347FQ33747406-79D522CD-DC4E-425E-AB32-5E5DE789879DQ34679227-F86B50FC-377C-4412-B490-61D7346687E2Q35177859-50322F00-E5E3-4E1E-A95F-BC08107E3B1EQ35895739-3BC8672C-B700-43C0-85A2-D9EFCB692E3FQ36532522-9F18626E-846B-4E49-A5A4-3DC71EE44EE5Q36533306-4DA71982-832F-42F3-8B64-62906C2518BEQ36611873-4A42E7FC-0C2D-4500-B988-8E5D42EF31CCQ36652629-B1DD0F40-690B-4298-9D11-910C42CE892BQ36941966-4FEE5112-5F26-43AE-8C1E-E8B88545A8FFQ37932556-359BCA59-891D-43B1-9D12-C48C7C73F513Q38873401-15DDB0EF-C2B5-4305-97BB-0C3D2CC4D96FQ39034857-95C1370B-0817-4EAC-9185-E00633205C69Q39464556-D7A22BBD-8A9B-456D-AEEC-D9E934A688A8Q39859449-60BB72B3-B004-45A3-BF73-9F092C5242B3Q40040202-64682BF1-4CAC-47CB-991D-80CC7DCECFCDQ40414506-F75688EC-C619-4FA5-A804-E7AC14AB1CBEQ41835248-F965ACC4-A3F8-4A67-8E47-AA715287EEB6Q47621525-DC23AD29-7A51-42D9-A89D-5C36072199ADQ50912597-7ADC103B-1AB2-431B-AF68-0BC437CFFAEAQ51441307-3BADB695-F9B2-497C-86B0-2D5301B93D05Q79856195-52A50A15-8E0B-4647-B384-F3A495C8BB2AQ84984963-54164184-D190-4B70-A5EC-68EFAB402A0BQ87433062-5DBF4B27-6994-4163-9B5A-13EEFA1751A9Q88777744-B6EEA2B4-3F13-4E14-AD62-532855D32745Q91450041-8E5C0513-5992-4DF5-A015-7A8736549A1BQ92722583-A2376D1C-F063-410E-B763-7680646825C2Q92935361-697FD835-E628-42BE-8EC7-6F4DBA224E6A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Jamieson
@ast
David Jamieson
@en
David Jamieson
@es
David Jamieson
@nl
type
label
David Jamieson
@ast
David Jamieson
@en
David Jamieson
@es
David Jamieson
@nl
prefLabel
David Jamieson
@ast
David Jamieson
@en
David Jamieson
@es
David Jamieson
@nl
P106
P21
P31
P496
0000-0002-3064-6713